Overview

Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium
Phase:
N/A
Details
Lead Sponsor:
Beijing Tiantan Hospital
Treatments:
Dexmedetomidine